Jefferies Financial Group Inc. Makes New $994,000 Investment in Revolution Medicines, Inc. (NASDAQ:RVMD)

Jefferies Financial Group Inc. purchased a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 22,725 shares of the company's stock, valued at approximately $994,000.

Other institutional investors have also made changes to their positions in the company. Barclays PLC raised its holdings in Revolution Medicines by 187.1% during the 3rd quarter. Barclays PLC now owns 294,664 shares of the company's stock worth $13,362,000 after purchasing an additional 192,021 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Revolution Medicines by 92.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 61,980 shares of the company's stock worth $2,711,000 after buying an additional 29,853 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Revolution Medicines by 9.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,931,114 shares of the company's stock worth $84,467,000 after buying an additional 167,997 shares during the period. Sandy Cove Advisors LLC acquired a new position in shares of Revolution Medicines during the 4th quarter worth about $1,837,000. Finally, Russell Investments Group Ltd. grew its position in shares of Revolution Medicines by 11.4% during the 4th quarter. Russell Investments Group Ltd. now owns 4,243 shares of the company's stock worth $186,000 after buying an additional 434 shares during the period. 94.34% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, COO Margaret A. Horn sold 3,058 shares of Revolution Medicines stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $119,384.32. Following the completion of the transaction, the chief operating officer now directly owns 153,533 shares in the company, valued at approximately $5,993,928.32. This trade represents a 1.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark A. Goldsmith sold 11,738 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $458,251.52. Following the completion of the sale, the insider now directly owns 441,564 shares in the company, valued at approximately $17,238,658.56. The trade was a 2.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,660 shares of company stock worth $650,406. 8.20% of the stock is owned by corporate insiders.

Revolution Medicines Stock Down 2.5%

Shares of RVMD stock traded down $1.02 during trading on Wednesday, hitting $39.45. The company had a trading volume of 202,773 shares, compared to its average volume of 1,486,502. The stock's 50-day moving average is $37.53 and its two-hundred day moving average is $42.93. The stock has a market capitalization of $7.35 billion, a price-to-earnings ratio of -10.98 and a beta of 1.11. Revolution Medicines, Inc. has a 52 week low of $29.17 and a 52 week high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($1.13) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.01). During the same period in the prior year, the firm earned ($0.70) earnings per share. On average, research analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on RVMD shares. Oppenheimer increased their target price on Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Needham & Company LLC reissued a "buy" rating and set a $57.00 target price on shares of Revolution Medicines in a research note on Thursday, May 8th. Wedbush reissued an "outperform" rating and set a $67.00 target price on shares of Revolution Medicines in a research note on Thursday, May 8th. Stifel Nicolaus lowered their target price on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Finally, Guggenheim reduced their price target on Revolution Medicines from $87.00 to $80.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $67.08.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.